By aligning multi-omic signals with niche topology, the EXT1 or EXT2 axis model offers a rigorous template for glyco-oncology in glioma and a roadmap for prospective validation in organoids, patient-derived xenografts, and early translational research. This evidence concerns the gene EXT1 and central nervous system cancer.